Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - efavirenz - tablet - 600mg

Malta - angličtina - Medicines Authority

1 a pharma gmbh - efavirenz 600 mg - film-coated tablet

Spojené štáty - angličtina - NLM (National Library of Medicine)

a-s medication solutions - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. coadminstration of atripla with voriconazole is contraindicated. efavirenz, a component of atripla, significantly decreases voriconazole plasma concentrations, and coadministration may decrease the therapeutic effectiveness of voriconazole. also, voriconazole significantly increases efavirenz plasma concentrations, which may increase the risk of efavirenz-associated side effects. because atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered [see clinical pharmacology (12.3) tables 4 and 5]. pregnancy category d [see warnings and precautions (5.9)] antiret

Spojené štáty - angličtina - NLM (National Library of Medicine)

doh central pharmacy - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] the centers for disease control and prevention recommend that hiv-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of hiv-1. studies in rats have demonstrated that both efavirenz and tenofovir are secreted in milk. it is n

Spojené štáty - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. for some drugs, competition for cyp3a by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression). drugs that are contraindicated with atripla are listed in table 1. pregnancy category d [see warnings and precautions (5.8)] antiretroviral pregnancy registry: to monitor fetal outcomes of pregnant women, an antiretroviral pregnancy registry has been established. physicians are encouraged to register patients who become pregnant by cal

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan specialty l.p. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 400 mg - symfi lo® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients weighing at least 35 kg. symfi lo is contraindicated: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to symfi lo during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-containing regimens in the first trimester of pregnancy. although a causal relationship has not been established between exposure to efv in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose. in addition, fetal and embryonic toxicities occurred in rats, at a dose ten times less than the human exposur

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan specialty l.p. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - symfi® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients weighing at least 40 kg. symfi is contraindicated: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to symfi during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-containing regimens in the first trimester of pregnancy. although a causal relationship has not been established between exposure to efv in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose. in addition, fetal and embryonic toxicities occurred in rats, at a dose ten times less than the human exposure at recom

Keňa - angličtina - Pharmacy and Poisons Board

laurus labs limited 2nd floor, serene chambers, road no.-7 banjara - efavirenz, lamivudine and tenofovir disoproxil… - dispersible tablet - efavirenz usp 400 mg, lamivudine usp 300 mg and… - lamivudine tenofovir disoproxil and efavirenz

Keňa - angličtina - Pharmacy and Poisons Board

laurus labs limited 2nd floor, serene chambers, road no.-7 banjara - efavirenz, lamivudine and tenofovir disoproxil… - film-coated tablet - efavirenz 600mg, lamivudine 300mg and tenofovir… - lamivudine tenofovir disoproxil and efavirenz

Malta - angličtina - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - tenofovir disoproxil, efavirenz, emtricitabine - film-coated tablet - tenofovir disoproxil 245 mg efavirenz 600 mg emtricitabine 200 mg - antivirals for systemic use